miR‑452‑5p and miR‑215‑5p expression levels in colorectal cancer tissues and their relationship with clinicopathological features

Yan,Jingbo; Wei,Ru; Li,Hui; Dou,Yan; Wang,Junhui

doi:10.3892/ol.2020.11845

miR‑452‑5p and miR‑215‑5p expression levels in colorectal cancer tissues and their relationship with clinicopathological features

Authors:
- Jingbo Yan
- Ru Wei
- Hui Li
- Yan Dou
- Junhui Wang
View Affiliations

Affiliations: Department of Pathology, Xingtai People's Hospital, Xingtai, Hebei 054031, P.R. China, Department of Microbiology and Immunology, Xingtai Medical College, Xingtai, Hebei 054000, P.R. China, Department of Surgery, Xingtai People's Hospital, Xingtai, Hebei 054031, P.R. China, Medical Records Room, Xingtai People's Hospital, Xingtai, Hebei 054031, P.R. China
Published online on: July 9, 2020 https://doi.org/10.3892/ol.2020.11845
Pages: 2955-2961
Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to investigate the expression levels of miR‑452‑5p and miR‑215‑5p in colorectal cancer tissues and their relationship with clinicopathological features. A total of 50 specimens of cancerous and adjacent normal tissues were collected from patients with colorectal cancer who underwent surgical resection at the Xingtai People's Hospital from March 2012 to February 2014. All specimens were confirmed by the Department of Pathology. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to measure the expression levels of miR‑452‑5p and miR‑215‑5p in cancerous and adjacent normal tissues. Moreover, the relationship of the expression levels of miR‑452‑5p and miR‑215‑5p with the clinicopathological features of patients with colorectal cancer was explored. The expression levels of both miR‑452‑5p and miR‑215‑5p in colorectal cancer tissues were significantly lower than those in adjacent normal tissues (P<0.05). miR‑452‑5p expression was related to tumor‑node‑metastasis (TNM) staging and differentiation degree in colorectal cancer tissues, and the expression of miR‑215‑5p was associated with TNM staging, lymph node metastasis and infiltration depth (P<0.05). The 5‑year overall survival (OS) rate in the miR‑452‑5p high‑expression group was significantly higher than that in the low‑expression group (P<0.05). The 5‑year OS rates in the miR‑215‑5p high‑ and low‑expression groups were 53.57% (15/28) and 40.91% (9/22), respectively, indicating that the 5‑year OS rate in the miR‑215‑5p high‑expression group was significantly higher than that in the low‑expression group. Cox proportional hazards regression model showed that TNM staging, lymph node metastasis, as well as miR‑452‑5p and miR‑215‑5p expression levels were independent risk factors affecting colorectal cancer prognosis (P<0.05), whereas the differentiation degree and infiltration depth were not (P>0.05). In conclusion, the expression levels of miR‑452‑5p and miR‑215‑5p were significantly downregulated in colorectal cancer tissues promoting the occurrence, progression, invasion and metastasis of colorectal cancer, which suggests that miR‑452‑5p and miR‑215‑5p could be used as prognostic indicators for patients with colorectal cancer.

View Figures

View References

1	Al Dahhan SA and Al Lami FH: Epidemiology of Colorectal Cancer in Iraq, 2002–2014. Gulf J Oncolog. 1:23–26. 2018.PubMed/NCBI
2	Abdulla MH, Valli-Mohammed MA, Al-Khayal K, Al Shkieh A, Zubaidi A, Ahmad R, Al-Saleh K, Al-Obeed O and McKerrow J: Cathepsin B expression in colorectal cancer in a Middle East population: Potential value as a tumor biomarker for late disease stages. Oncol Rep. 37:3175–3180. 2017. View Article : Google Scholar : PubMed/NCBI
3	Vatandoust S, Price TJ and Karapetis CS: Colorectal cancer: Metastases to a single organ. World J Gastroenterol. 21:11767–11776. 2015. View Article : Google Scholar : PubMed/NCBI
4	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66:683–691. 2017. View Article : Google Scholar : PubMed/NCBI
5	Li CX, An XX, Zhao B, Wu SJ, Xie GH and Fang XM: Impact of operation timing on post-operative infections following colorectal cancer surgery. ANZ J Surg. 86:294–298. 2016. View Article : Google Scholar : PubMed/NCBI
6	Katsidzira L, Gangaidzo I, Thomson S, Rusakaniko S, Matenga J and Ramesar R: The shifting epidemiology of colorectal cancer in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2:377–383. 2017. View Article : Google Scholar : PubMed/NCBI
7	Legrand N, Dixon DA and Sobolewski C: AU-rich element-binding proteins in colorectal cancer. World J Gastrointest Oncol. 11:71–90. 2019. View Article : Google Scholar : PubMed/NCBI
8	Govaert JA, van Dijk WA, Fiocco M, Scheffer AC, Gietelink L, Wouters MW and Tollenaar RA: Nationwide outcomes measurement in colorectal cancer surgery: Improving quality and reducing costs. J Am Coll Surg. 222:19–29.e2. 2016. View Article : Google Scholar : PubMed/NCBI
9	Curtis NJ, Taylor M, Fraser L, Salib E, Noble E, Hipkiss R, Allison AS, Dalton R, Ockrim JB and Francis NK: Can the combination of laparoscopy and enhanced recovery improve long-term survival after elective colorectal cancer surgery? Int J Colorectal Dis. 33:231–234. 2018. View Article : Google Scholar : PubMed/NCBI
10	Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, et al: Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet. 43:371–378. 2011. View Article : Google Scholar : PubMed/NCBI
11	Bhome R, Del Vecchio F, Lee G-H, Bullock MD, Primrose JN, Sayan AE and Mirnezami AH: Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Lett. 420:228–235. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhai W, Li S, Zhang J, Chen Y, Ma J, Kong W, Gong D, Zheng J, Xue W and Xu Y: Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals. Mol Cancer. 17:1572018. View Article : Google Scholar : PubMed/NCBI
13	Liu L, Chen K, Wu J, Shi L, Hu B, Cheng S, Li M and Song L: Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas. Clin Cancer Res. 19:3429–3438. 2013. View Article : Google Scholar : PubMed/NCBI
14	He Z, Xia Y, Pan C, Ma T, Liu B, Wang J, Chen L and Chen Y: Up-regulation of MiR-452 inhibits metastasis of non-small cell lung cancer by regulating BMI1. Cell Physiol Biochem. 37:387–398. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wang C, Chen Q, Li S, Li S, Zhao Z, Gao H, Wang X, Li B, Zhang W, Yuan Y, et al: Dual inhibition of PCDH9 expression by miR-215-5p up-regulation in gliomas. Oncotarget. 8:10287–10297. 2017. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Simon K: Colorectal cancer development and advances in screening. Clin Interv Aging. 11:967–976. 2016. View Article : Google Scholar : PubMed/NCBI
18	Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, et al: The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. 65:977–989. 2016. View Article : Google Scholar : PubMed/NCBI
19	Yang S, Sun Z, Zhou Q, Wang W, Wang G, Song J, Li Z, Zhang Z, Chang Y, Xia K, et al: MicroRNAs, long noncoding RNAs, and circular RNAs: Potential tumor biomarkers and targets for colorectal cancer. Cancer Manag Res. 10:2249–2257. 2018. View Article : Google Scholar : PubMed/NCBI
20	Wolter JM, Le HH, Linse A, Godlove VA, Nguyen TD, Kotagama K, Lynch A, Rawls A and Mangone M: Evolutionary patterns of metazoan microRNAs reveal targeting principles in the let-7 and miR-10 families. Genome Res. 27:53–63. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wei W, Yang Y, Cai J, Cui K, Li RX, Wang H, Shang X and Wei D: miR-30a-5p suppresses tumor metastasis of human colorectal cancer by targeting ITGB3. Cell Physiol Biochem. 39:1165–1176. 2016. View Article : Google Scholar : PubMed/NCBI
22	Gan XN, Gan TQ, He RQ, Luo J, Tang RX, Wang HL, Zhou H, Qing H, Ma J, Hu XH, et al: Clinical significance of high expression of miR-452-5p in lung squamous cell carcinoma. Oncol Lett. 15:6418–6430. 2018.PubMed/NCBI
23	Kolligs FT: Diagnostics and Epidemiology of Colorectal Cancer. Visc Med. 32:158–164. 2016. View Article : Google Scholar : PubMed/NCBI
24	Ullmann P, Nurmik M, Schmitz M, Rodriguez F, Weiler J, Qureshi-Baig K, Felten P, Nazarov PV, Nicot N, Zuegel N, et al: Tumor suppressor miR-215 counteracts hypoxia-induced colon cancer stem cell activity. Cancer Lett. 450:32–41. 2019. View Article : Google Scholar : PubMed/NCBI
25	Bouvier AM and Launoy G: Epidemiology of colorectal cancer. Rev Prat. 65:767–773. 2015.(In French). PubMed/NCBI
26	Gao L, Gan XN, Ye ZH, et al: MiR-452-5p may serve as an oncogene in colorectal cancer through targeting CDKN1B: A study based on bioinformatics analysis and dual-luciferase reporter assay. Int J Clin Exp Med. 12:2151–2166. 2019.
27	Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, Brchnelova D, Slaba K, Svoboda M, Halamkova J, et al: MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. Oncogenesis. 6:3992017. View Article : Google Scholar : PubMed/NCBI
28	He Z, Xia Y, Liu B, Qi X, Li Z, Wang J, Chen L and Chen Y: Down-regulation of miR-452 is associated with poor prognosis in the non-small-cell lung cancer. J Thorac Dis. 8:894–900. 2016. View Article : Google Scholar : PubMed/NCBI
29	Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT and Helland Å: Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol. 57:1225–1231. 2018. View Article : Google Scholar : PubMed/NCBI